Literature DB >> 7656274

Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo.

H Belfrage1, M Dohlsten, G Hedlund, T Kalland.   

Abstract

The bacterial superantigen, staphylococcal enterotoxin A (SEA) activates T cells with high frequency and directs them to lyse MHC-class-II-expressing cells in superantigen-dependent cell-mediated cytotoxicity (SDCC). Treatment of mice with SEA induced strong CD8+ T-cell(CTL)-mediated SDCC, as well as abundant cytokine production from CD4+ and CD8+ T cells. However, both cytotoxicity and cytokine release were transient. In contrast, combined treatment with SEA and recombinant interleukin-2 (rIL-2) increased peak levels and maintained CTL activity. These effects were concomitant with an increased number of SEA-reactive V beta 11+ T cells. Both the CD4+ and CD8+ populations contained higher frequencies of cells expressing IL-2 receptor (IL-2R) alpha beta, which suggests that continuous IL-2R signaling preserves its high expression and subsequently prevents loss of growth factor signals necessary for expansion of T cells. Although IL-2R expression was increased among both CD4+ and CD8+ cells, only the cytotoxic function of CTL, but not cytokine production from either CD4 or CD8, was augmented. These findings demonstrate that treatment with rIL-2 potentiates superantigen-induced cytotoxicity and maintains high CTL activity. rIL-2 might therefore be useful in improving superantigen-based tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656274     DOI: 10.1007/bf01527404

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells.

Authors:  G Hedlund; M Dohlsten; T Herrmann; G Buell; P A Lando; S Segrén; J Schrimsher; H R MacDonald; H O Sjögren; T Kalland
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

2.  Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo.

Authors:  H R MacDonald; S Baschieri; R K Lees
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

3.  Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

Authors:  S Webb; C Morris; J Sprent
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

4.  In vivo administration of interleukin 1 elicits increased Ia antigen expression on B cells through the induction of interleukin 4.

Authors:  L M Killar; C A Hatfield; S R Carding; M Pan; G E Winterrowd; K Bottomly
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

5.  Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B.

Authors:  Y Kawabe; A Ochi
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

6.  An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction.

Authors:  B Fleischer; R Gerardy-Schahn; B Metzroth; S Carrel; D Gerlach; W Köhler
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

7.  Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway.

Authors:  J A Gonzalo; I Moreno de Alborán; J E Alés-Martínez; C Martínez; G Kroemer
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

8.  Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines.

Authors:  S Baschieri; R K Lees; A R Lussow; H R MacDonald
Journal:  Eur J Immunol       Date:  1993-10       Impact factor: 5.532

9.  Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.

Authors:  M Dohlsten; M Björklund; A Sundstedt; G Hedlund; D Samson; T Kalland
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

10.  Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.

Authors:  M Dohlsten; L Abrahmsén; P Björk; P A Lando; G Hedlund; G Forsberg; T Brodin; N R Gascoigne; C Förberg; P Lind
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

View more
  1 in total

1.  Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo.

Authors:  H Belfrage; M Dohlsten; G Hedlund; T Kalland
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.